# FORM 7

## MONTHLY PROGRESS REPORT

Name of Listed Issuer: Lexington Biosciences, Inc. (the "**Issuer**").

Trading Symbol: LNB

Number of Outstanding Listed Securities: 37,978,401

Date: September 3, 2018 (for the month ended August 31, 2018)

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

### General Instructions

(a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.

(b) The term "Issuer" includes the Issuer and any of its subsidiaries.

(c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

### Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

   **During the month of August, the Company focused on recruiting clinical trial sites for its upcoming multi-center clinical study. On August 21st, 2018 the Company announced a partnership with the Medical College of Wisconsin for its multi-center clinical study.**

**Additionally, in the month of August the Issuer continued its investment roadshow and outreach activities to eligible brokers and investment advisors in the United States and Canada. On August 27th, the Company announced the termination of its brokered private placement with Gravitas Securities, along with announcing an upcoming non-brokered private placement.**

2. Provide a general overview and discussion of the activities of management.

   **Management focused on fundraising activities in addition to support of its clinical studies for clearance of the HeartSentry device by the US FDA. Additionally, management is developing the commercialization and reimbursement strategy plans for the company for HeartSentry market introduction. The Issuer is developing a new and disruptive product for measuring endothelial function as a long-term predictor of cardiovascular system health.**

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

   **No new products or services developed other than ongoing development and clinical investigation of HeartSentry.**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

   **No products discontinued.**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

   **On August 21st, 2018 the Company announced a partnership with the Medical College of Wisconsin for its multi-center clinical study. Relationship is not with a Related Person and the agreement consists of payments for fulfillment of clinical trial services.**

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

   **On August 27th, the Company announced the termination of its brokered private placement with Gravitas Securities, along with announcing an upcoming non-brokered private placement.**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State

how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**No acquisitions or dispositions to report.**

8. Describe the acquisition of new customers or loss of customers.

**No new customers acquired or lost.**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**None to report.**

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

**No employee hirings, terminations, or lay-offs.**

11. Report on any labour disputes and resolutions of those disputes if applicable.

**No labor disputes.**

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**No party to any legal proceeding.**

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**The Company received an advance totalling $50,000 from a shareholder of the Company. It is the Shareholder's intention to convert the amount advanced into Units as part of the upcoming non-brokered private placement announced on August 27, 2018. Other than that there is no indebtedness other than normal accounts payable.**

14. Provide details of any securities issued and options or warrants granted.

**Nothing to report.**

15. Provide details of any loans to or by Related Persons.

**The Company received an advance totalling $50,000 from a shareholder of the Company. It is the Shareholder's intention to convert the amount advanced into Units as part of the upcoming non-brokered private placement announced on August 27, 2018. Other than that there is no indebtedness other than normal accounts payable.**

16. Provide details of any changes in directors, officers or committee members.

**Nothing to report.**

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

**The Issuer's business involves certain risks and uncertainties that are inherent to the Issuer's industry. Please refer to the "Risk Factors" section of the Listing Statement dated March 31, 2017, which is available on the Canadian Securities Exchange's website at www.thecse.com. Please also refer to the "Critical Risk Factors" section of the Issuer's management discussion and analysis for the period ended December 31, 2016 and for the three months ended March 31, 2017, both are available under the Issuer's SEDAR profile at www.sedar.com.**

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.

2. As of the date hereof there were no material information concerning the Issuer which has not been publicly disclosed.

3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).

4. All of the information in this Form 7 Monthly Progress Report is true.

Dated September 3, 2018.

Eric Willis
Name of Director or Senior Officer

Signature
Chief Executive Officer
Official Capacity

| ***Issuer Details***<br>Name of Issuer<br>Lexington Biosciences, Inc. | For Month End<br>August 2018 | Date of Report<br>YY/MM/DD<br>18/03/09 |
|---|---|---|
| Issuer Address<br>Suite 1900 - 1055 West Hastings Street | | |
| City/Province/Postal Code<br><br>Vancouver BC Canada, V6E 2E9 | Issuer Fax No.<br>n/a | Issuer Telephone No.<br>(800) 320-2640 |
| Contact Name<br><br>Eric Willis | Contact Position<br>CEO | Contact Telephone No.<br>(800) 320-2640 |
| Contact Email Address<br>ewillis@lexingtonbiosciences.com | Web Site Address<br>www.lexingtonbiosciences.com | |